overweight or obese
Conditions
Interventions
Case series:None
Sponsors
Nanchang First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age= 18 years old, gender is not limited; (2) Subject 24.0 kg/m2= body mass index (BMI)<28.0 kg/m2 [body mass index BMI=weight (kg)/height 2(m2)] at screening, with at least one weight-related comorbidity, or body mass index (BMI=28.0kg/m2, with or without comorbidities; and stable body weight (less than 5% self-reported weight change within 3 months); (3) Patients with overweight/obesity with comorbidities such as hypertension, diabetes mellitus, and dyslipidemia must meet the relevant disease diagnostic criteria (please refer to the guidelines for the prevention and management of primary hypertension at the national level (2020 edition), the guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition) and the guidelines for the management of blood lipids in China (2023), among which overweight/obesity with diabetes mellitus must have glycosylated hemoglobin (HbA1c) test results within 1 month before enrollment; (4) First treatment with liraglutide injection (rilupine); (5) Voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2); (2) Have a history of severe allergy to liraglutide or any excipient component of this product; (3) Participation in any other clinical trial currently or within the past 1 month; (4) Not suitable to participate in this study as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| weight; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index;waistline;Hip circumference;Depression Rating Scale (PHQ-9) score;Glycosylated hemoglobin;Fasting blood glucose;Blood pressure;blood lipids;Echocardiographic indicators;Blood glucose 2 hours postprandial;Fasting insulin;Fasting C-peptide;electrocardiogram;Complete blood count;Blood biochemistry;Urinalysis;Markers of heart failure;Serum creatinine;Protein in the urine; | — |
Countries
China
Contacts
Public ContactHu Ling
Nanchang First Hospital
Outcome results
None listed